Mills Anne M, E Gottlieb Chelsea, M Wendroth Scott, M Brenin Christiana, Atkins Kristen A
Departments of *Pathology †Hematology/Oncology, University of Virginia, Charlottesville, VA.
Am J Surg Pathol. 2016 Aug;40(8):1109-16. doi: 10.1097/PAS.0000000000000671.
Apocrine carcinomas comprise ∼1% of all breast cancers and are characterized by large cells bearing abundant eosinophilic granular cytoplasm, round nuclei, and prominent nucleoli. They are typically estrogen receptor/progesterone receptor/HER2 negative, making them unresponsive to typical hormonal or HER2-based chemotherapy. However, this subtype of triple-negative breast cancers expresses androgen receptor (AR), a feature not shared by most nonapocrine triple-negative cancers (NA-TNCs). AR therefore represents a potential diagnostic tool and therapeutic target for apocrine breast carcinoma. All pure apocrine carcinomas diagnosed during a 10-year period were reviewed, and clinicopathologic characteristics were compared with a control group of 26 NA-TNC cases. Twenty apocrine carcinomas were identified (∼0.8% of all breast cancers). The mean age at diagnosis was 69.3 years for apocrine carcinomas and 56.7 years for NA-TNC. All apocrine carcinomas and no NA-TNC were AR positive. The proportions of apocrine carcinoma grades varied, with G1 being seen in 15% of patients, G2 in 55%, and G3 in 30%. In contrast, 100% of NA-TNC cases were G3. The majority of apocrine carcinomas presented at low T stage (T1: 70%; T2: 20%; T3: 10%; T4: 0%), whereas NA-TNC cases more often presented at T2 or higher (T1: 46.2%; T2: 30.8%; T3: 11.5%; T4: 11.5%). Thirty percent of apocrine carcinomas and 30.8% of NA-TNCs had nodal metastases at presentation. Apocrine carcinomas had a favorable clinical prognosis, with 80% of patients showing no evidence of disease-related morbidity or mortality (mean follow-up: 45.2 mo). Pure apocrine carcinomas represent a clinicopathologically distinct subgroup of triple-negative breast cancer characterized by AR positivity. When compared with NA-TNC, apocrine carcinomas more often present in older women with lower grade and T stage, a group in which a more conservative treatment regimen is often desired.
大汗腺癌约占所有乳腺癌的1%,其特征为细胞大,具有丰富的嗜酸性颗粒状细胞质、圆形细胞核和明显的核仁。它们通常雌激素受体/孕激素受体/HER2阴性,这使得它们对典型的激素或基于HER2的化疗无反应。然而,这种三阴性乳腺癌亚型表达雄激素受体(AR),这是大多数非大汗腺三阴性癌(NA-TNCs)所没有的特征。因此,AR是大汗腺癌潜在的诊断工具和治疗靶点。回顾了10年间诊断的所有纯大汗腺癌,并将其临床病理特征与26例NA-TNC病例的对照组进行比较。共鉴定出20例大汗腺癌(约占所有乳腺癌的0.8%)。大汗腺癌的诊断时平均年龄为69.3岁,NA-TNC为56.7岁。所有大汗腺癌均为AR阳性,而NA-TNC均为AR阴性。大汗腺癌的分级比例各不相同,15%的患者为G1级,55%为G2级,30%为G3级。相比之下,100%的NA-TNC病例为G3级。大多数大汗腺癌处于低T分期(T1:70%;T2:20%;T3:10%;T4:0%),而NA-TNC病例更多处于T2期或更高分期(T1:46.2%;T2:30.8%;T3:11.5%;T4:11.5%)。30%的大汗腺癌和30.8%的NA-TNC在初诊时有淋巴结转移。大汗腺癌具有良好医的临床预后,80%的患者无疾病相关发病或死亡证据(平均随访:45.2个月)。纯大汗腺癌是三阴性乳腺癌中一个临床病理特征独特的亚组,其特点是AR阳性。与NA-TNC相比,大汗腺癌更常见于年龄较大、分级和T分期较低的女性,这一群体通常希望采用更保守的治疗方案。